Mark C. Genovese

机构：Eli Lilly (United States), Gilead Sciences (United States) · ORCID：0000-0001-5294-4503

发表论文 435 篇 · 总被引 33936 次 · h-index 89

代表论文

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis (2021 · Arthritis Care & Research · 被引 1350)
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis (2021 · Arthritis & Rheumatology · 被引 1071)
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial (2021 · Annals of the Rheumatic Diseases · 被引 252)
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years (2021 · Annals of the Rheumatic Diseases · 被引 81)
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study (2021 · Annals of the Rheumatic Diseases · 被引 76)
Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study (2021 · The Lancet Rheumatology · 被引 75)